iifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Lupin Launches Generic Mybetriq in US, Eyes Robust Sales Growth

22 Apr 2024 , 03:21 PM

Lupin announced the launch of Mirabegron, a generic version of Mybetriq, to treat overactive bladder in the United States, following approval from the USFDA.

Mirabegron, manufactured by Astellas Pharma Global Development, is Lupin's generic equivalent of Myrbetriq and will be produced at its facility in Nagpur, India.

Myrbetriq, a prescription medicine, is used to treat overactive bladder symptoms like frequent or urgent urination and urinary incontinence, including neurogenic detrusor overactivity (NDO) in children.

According to IQVIA MAT February 2024, Mirabegron recorded estimated annual sales of $1,019 million in the US.

Lupin's Executive Director anticipates quarterly US sales of $200–210 million this year, with North America contributing approximately 37% to Lupin's sales, and India accounting for around 34%.

Lupin recently launched the first generic version of Oracea (Doxycycline capsules, 40 mg) in the US, used to treat inflammatory lesions of rosacea in adult patients.

The company also successfully concluded inspections by the USFDA at its manufacturing facility in Vadodara, Gujarat.

Lupin operates globally, developing and commercializing branded and generic formulations, biotechnology products, and APIs across various markets.

Lupin shares were trading at nearly 3.21% higher on Monday at ₹1,595 apiece on the NSE, with a year-to-date surge of nearly 21.64% and a one-year gain of 127.47%.

For feedback and suggestions, write to us at editorial@iifl.com

Related Tags

  • Lupin
  • Lupin News
  • USFDA
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Most Read News

Awfis IPO oversubscribed 4.19x on day two
23 May 2024|09:51 PM
Indian markets end the day on high
23 May 2024|03:59 PM
Markets surge

Markets surge

Whatsapp
Facebook
Twitter
LinkedIn
23 May 2024|03:45 PM
MG Motor India to supply 3000 EVs to Vertelo
23 May 2024|03:46 PM
Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.